Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.
 
> (-)-Epigallocatechin [970-74-1]

(-)-Epigallocatechin [970-74-1]

Afdrukken Afdrukken
Log in alstublieft

Referentie HY-N0225-500mg

Formaat : 500mg

Merk : MedChemExpress


Description

(-)-Epigallocatechin (Epigallocatechin) is the most abundant flavonoid in green tea, can bind to unfolded native polypeptides and prevent conversion to amyloid fibrils.

Cellular Effect
Cell Line Type Value Description References
BV-2 IC50
> 100 μM
Compound: 14
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction
[PMID: 27623545]
H9 IC50
1.8 μg/mL
Compound: 7
Inhibition of uninfected H9 lymphocytic cell growth
Inhibition of uninfected H9 lymphocytic cell growth
10.1016/0960-894X(96)00095-9
HUVEC IC50
8 μM
Compound: 42
Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells
Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells
10.1007/s00044-012-0353-y
MT4 CC50
16.1 μg/mL
Compound: 13
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 10425115]
MT4 IC50
> 16.1 μg/mL
Compound: 13
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
[PMID: 10425115]
In Vitro

(-)-Epigallocatechin (EGC) is a potent inhibitor of amyloidogenic cystatin I66Q amyloid fibril formation in vitro. Computational analysis suggests that (-)-Epigallocatechin prevents amyloidogenic cystatin fibril formation by stabilizing the molecule in its native-like state as opposed to redirecting aggregation to disordered, amorphous aggregates [1]. Combined curcumin and EGCG treatment reduced the cancer stem-like Cluster of differentiation 44 (CD44)-positive cell population. Western blot and immunoprecipitation analyses revealed that curcumin and (-)-Epigallocatechin (EGC) specifically inhibited STAT3 phosphorylation and STAT3-NFkB interaction was retained [2]. (-)-Epigallocatechin (EGC) exhibits a MIC and MBC of 5 μg/mL and 20 μg/mL respectively and effectively eradicated E. faecalis biofilms. (-)-Epigallocatechin induces the formation of hydroxyl radicals in E. faecalis. The addition of DIP protected E. faecalis against EGCG-mediated antibacterial effects. At sub-MIC, (-)-Epigallocatechin induces significant down-regulation of E. faecalis virulence genes [3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(-)-Epigallocatechin Related Antibodies

Solvant et solubilité
In Vitro: 

DMSO : 66.67 mg/mL (217.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2651 mL 16.3255 mL 32.6509 mL
5 mM 0.6530 mL 3.2651 mL 6.5302 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références